Biomarker risk assessment model identified high-risk patients with cancer who benefit from thromboprophylaxis.
rct · Level II
Where this comes from
- Record sourced from PubMed, PMID 38315999.
- Also identified by DOI 10.7326/J23-0121.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Alexander M, Harris S, Underhill C, et al. <b>Risk-directed ambulatory thromboprophylaxis in lung and gastrointestinal cancers: the TARGET-TP randomized clinical trial.</b> JAMA Oncol. 2023;9:1536-1545. 37733336.
Medical subject headings
- Neoplasms
- Venous Thromboembolism